Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul-Aug;35(4):360-366.
doi: 10.1016/j.clindermatol.2017.03.008. Epub 2017 Mar 24.

Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders

Affiliations
Review

Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders

Jonathan I Silverberg. Clin Dermatol. 2017 Jul-Aug.

Abstract

Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease with substantial morbidity and quality of life impairment. There are a number of comorbid health problems that occur in patients with AD, aside from the cutaneous signs and symptoms. Chronic pruritus and inflammation can lead to sleep disturbances and mental health symptoms, which are not mutually exclusive. AD is associated with and may predispose to higher risk of other atopic disorders, including asthma and hay fever. Persons with AD appear to be at higher risk for multiple neuropsychiatric disorders, including depression, attention-deficit/hyperactivity disorder, speech disorders in childhood, headaches, and seizures. There is also a multifactorial association of AD with osteoporosis, injuries, and fractures. Elucidating the comorbidities of AD is important for disease management and improving overall clinical outcomes. This review summarizes recent developments in the atopic and neuropsychiatric comorbidities of AD.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Silverberg received consulting fees from AbbVie, Anacor Pharmaceuticals, Eli Lilly, Galderma, GlaxoSmithKline, MedImmune, Pfizer, Procter & Gamble, Realm Therapeutics, and Sanofi-Regeneron Pharmaceuticals and served as an investigator in trials sponsored by Abbvie, Celgene, GlaxoSmithKline, Eli Lilly, Regeneron Pharmaceuticals, and Roche

References

    1. Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis: contact, atopic, occupational, drug: official journal of the American Contact Dermatitis Society, North American Contact Dermatitis Group. 2014;25:107–114. - PMC - PubMed
    1. Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. The Journal of investigative dermatology. 2015;135:56–66. - PubMed
    1. De Benedetto A, Kubo A, Beck LA. Skin barrier disruption: a requirement for allergen sensitization? The Journal of investigative dermatology. 2012;132:949–963. - PMC - PubMed
    1. Flohr C, Perkin M, Logan K, et al. Atopic dermatitis and disease severity are the main risk factors for food sensitization in exclusively breastfed infants. The Journal of investigative dermatology. 2014;134:345–350. - PMC - PubMed
    1. Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. The Journal of allergy and clinical immunology. 2014;134:818–823. - PMC - PubMed

MeSH terms